VANCOUVER, BC – BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) announced today that Dr. Mark Day, chief executive officer, will present at the 16th International Postgraduate Course on Lysosomal Storage Disorders, in Nierstein (Mainz), Germany on June 07 – 10, 2017.
Dr. Day’s presentation, “Improving the Probability of Success in CNS Drug Discovery and Development: A Case Study,” targets issues relating to therapies to treat the central nervous system (CNS). The workshop is academic in nature and will be attended by scientists from companies and institutions that are focused on lysosomal storage diseases.
Lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders, some of which cause significant impairments in neurological function. The disorders are caused by dysfunctional or missing enzymes that are required for the processing and removal of unwanted cellular materials.
Several LSDs can be treated with enzyme replacement therapy, the intravenous infusion of a solution containing the missing enzyme. However, the blood-brain barrier blocks most therapeutics, including enzymes, from entering the CNS in sufficient quantities to effectively treat neurological disorders. The inability of most therapeutics to enter the CNS has resulted in areas of great unmet medical need.
“Our Transcend peptide technology specifically addresses the issue of delivery of therapeutics across the blood-brain barrier,” said Dr. Mark Day, CEO of biOasis. “From the preclinical data we’ve generated to date, we are excited to move several targets, including enzymes, antibodies and small molecules, through de-risking imaging studies and into clinical assessment. This workshop allows me to meet with many of the stakeholders in this very key market for us.”
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the brain-blood barrier. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.”
Source: biOasis Technologies Inc.